Podcasts about indications

Gal Gadot (The Runner, Wonder Woman, Fast & Furious) is an actor, action star, and former pageant winner. Gal joins Armchair Expert to discuss unexpectedly winning a beauty pageant, being thrust onto the front page of the New York Post at 21, and surviving cerebral venous thrombosis after the birth of her fourth child. Gal and Dax talk about being discovered for a Bond audition while studying law, reaching the point where she was ready to quit acting, and going from recovering in bed to training with an Olympic running coach for The Runner. Gal explains why struggle is essential to happiness, how parenthood constantly forces you to adapt, and why getting older can open you up emotionally.Thank you to our presenting partner Lilly. Lilly's Foundayo™(orforglipron). Advertisement Disclaimer: Please see Indications and Safety Summary with Warnings for Foundayo™(orforglipron) at https://www.foundayo.lilly.com/risk Start your 2 month free trial today: https://youtube.com/premium . Terms Apply. Cancel Anytime.Check Allstate first for a quote that could save you hundreds: https://www.allstate.com/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Midazolam is a familiar drug in anesthesia, but knowing when to use it — and when not to — requires more than understanding its sedative effects. In this installment of our series on anesthesia, Dr. Jake Stucki joins us to review Midazolam. Starting with what it is and how it works, we explore its onset, duration, and effects, how it is metabolized, and what it does and does not help with. We also cover indications, patient selection, administration and dosing, and why the anticipated duration of a procedure matters. From desired effects to potential adverse reactions, we discuss precautions, emergency measures, and how clinicians can use patient monitoring to make adjustments when managing adverse effects. Finally, we examine cases where Midazolam may not be the most appropriate intervention and what alternatives or considerations may come into play.Key Points From This Episode:Basics of Midazolam: onset, duration, and effects.What it does and doesn't help with.Its mechanism of action.How it is metabolized.Indications and which patients do and do not have this drug administered to them.Administration and dosing. Considering the duration of the procedure. Desired and undesired effects of Midazolam.Precautions and emergency measures. Using your monitors to make adjustments to manage adverse effects.More cases where Midazolam may not be the most appropriate intervention. Links Mentioned in Today's Episode:Dr. Jake Stucki — https://www.linkedin.com/in/jake-stucki-ab19a593/ Case Western Reserve University — https://case.edu/ Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059

When a child presents with sleep-disordered breathing, chronic mouth breathing, or persistent feeding challenges, evaluating the upper airway becomes a top priority. However, determining when conservative management is sufficient versus when surgical intervention - like a tonsillectomy or adenoidectomy - is required can be complex for both parents and providers.In this episode, Hallie Bulkin sits down with pediatric ENT specialist Dr. Ariel Grobman to break down the clinical nuances of pediatric airway evaluation. Dr. Grobman shares expert insights into physical examination techniques, the practical role of nasoendoscopy, and when sleep studies are truly necessary versus when visual and functional markers dictate action.Together, they explore post-surgical recovery expectations, adenoid regrowth, secondary causes of nasal obstruction like enlarged turbinates, and the critical link between airway dysfunction, ear infections, and feeding difficulties. Dr. Grobman also emphasizes the essential role of interdisciplinary collaboration between ENTs, myofunctional therapists, and airway-focused orthodontists.About the Guest: Ariel Grobman, MDDr. Ariel Grobman is a board-certified Otolaryngologist (Ear, Nose, and Throat surgeon) specializing in pediatric and adult airway management, sinus disorders, and head and neck surgery. Dr. Grobman is dedicated to taking an integrative, patient-centered approach to airway health, helping families navigate complex decisions regarding tonsillectomy, adenoidectomy, and nasal airway procedures. He works closely with multidisciplinary teams of speech pathologists, myofunctional therapists, and dentists to ensure comprehensive, root-cause care.Key Topics & TakeawaysAirway Risk Assessment: Why establishing danger and the severity of airway restriction is the primary step in evaluating pediatric sleep issues.Surgical Indications & Outcomes: Understanding real-world expectations, recovery protocols, and regrowth potential following tonsillectomy and adenoidectomy.Interdisciplinary Collaboration: Why optimal patient outcomes rely on close coordination between ENTs, airway-focused orthodontists, and myofunctional providers.Soundbites"Assessing danger and functional impact is always the most important first step.""A detailed physical exam combined with clinical history can often replace the need for a cumbersome sleep study.""Nasal endoscopy is quick, minimally invasive, and gives us immediate answers about structural obstructions."Timestamps01:03 - Guest Introduction: Dr. Ariel Grobman02:46 - Assessing Tonsils & Adenoids in Pediatric Patients06:51 - Indications for Pediatric Sleep Studies07:11 - Physical Examination & In-Office Nasal Endoscopy15:54 - Adenoidectomy vs. Tonsillectomy: Procedures & Recovery20:40 - Tissue Regrowth & Root Causes of Adenotonsillar Hypertrophy22:13 - Addressing Persistent Mouth Breathing & Role of Myofunctional Therapy36:56 - Managing Complex Pediatric Airway & Feeding Cases40:29 - Indications for Middle Ear Fluid Drainage & PE Tubes44:34 - Airway-Focused Orthodontics & Palatal Expansion49:09 - Where to Find Dr. Ariel Grobman & Closing RemarksLinks & ResourcesConnect with Dr. Ariel Grobman: Learn more about his practice and patient resources at Ariel Grobman MD.Fast Myo Screening Tool: Identify structural airway red flags and breathing compensations at FastMyoScreening.com.WORTH A LISTEN: CONTINUE YOUR JOURNEYDon't Ignore the Snore: The Hidden Link Between Airway, Sleep, and ADHD.Mouth Breathing vs. Nasal Breathing: Changing Lives Through Early Airway Intervention.STAY CONNECTED

"They're really worried that radiation is going to be painful. So they come in for that first day of treatment very anxious. With our patients with brain cancer, we're using the masks on the table, and those masks are very tight and hold their heads very, very still. So they'll be very worried about being claustrophobic. We may start out the first day or two with a little bit of [lorazepam]. And they'll come to me and they'll say, 'This really hasn't been as bad as I thought it was going to be,'" ONS member Catherine McCluskey, BSN, RN, OCN®, ROCN™, radiation oncology staff nurse at Atrium Health Wake Forest Baptist in Winston-Salem, NC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, who was the manager of oncology nursing practice at ONS at the time of the recording, during a conversation about radiation side effects in central nervous system (CNS) cancers. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 21, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat CNS cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Radiation Site-Specific Side Effects series Episode 306: Cancer Symptom Management Basics: CNS Toxicities ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy CNS Survivorship Needs More Research, Funding, and Training, Expert Panel Says Here's What the Updated CTCAE Version 6.0 Means for Oncology Nurses Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: Indications of Targeted Radiotherapy to the Brain and Spine: 2025 ONS Congress® Session ONS ROCN™ Certification Review™ ONS/ONCC® Radiation Therapy Certificate™ Supporting Radiation Side Effect Management Through ONS Evidence-Based Resources: 2025 ONS Congress® Session Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Radiation Necrosis: A Differential Diagnosis Dilemma The Neurocognitive Late Effects of Cranial Radiation Therapy: The Often-Unrecognized Outcomes Oncology Nursing Forum article: Symptom Clusters in Patients With Brain Tumors Undergoing Proton Beam Therapy ONS Huddle Cards: External Beam Radiation Proton Therapy Proton Therapy Radiation ONS Guidelines™ and Symptom Management Resources Cognitive impairment Fatigue Mucositis Radiodermatitis ONCC resources: Big List of CE Radiation Oncology Certified Nurse (ROCN™) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Patient Health Questionnaire (PHQ-9 and PHQ-2) To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "With primary tumors—glioblastomas, astrocytoma, all of those types of cancerous primary CNS tumors, the tumors are not very well-defined. They have little tentacles that kind of go out, so doing something like Gamma Knife, which is very precise, is not as effective as an external beam because the external beam will deliver radiation to all those little tentacles that are out there in the brain. And with Gamma Knife, you really can't effectively do that." TS 2:34 "When we're doing radiation to the brain, fortunately there aren't that many acute toxicities involved. Sometimes they'll have some mild dermatitis. Usually, it's not very significant. They, like everyone else who gets radiation, will have fatigue. Usually once we get to the end of the second week of radiation, into the third week for our patients with primary CNS tumors—the hair loss—they'll start to notice hair loss just in the treatment area. But those are typical, the things that we've seen most. Sometimes we'll have patients who will experience some nausea, maybe a few headaches, but really the acute toxicities are not severe typically with our patients with brain tumors." TS 8:30 "[For] the fatigue, I tell patients to just listen to their bodies. We don't want them to be sedentary, and we want them to go out and continue living their lives. But I do warn them that the fatigue is pretty much common to all patients receiving radiation at various degrees, depending on the patient. I just tell them to do what they feel like doing, and then when they're tired to rest, and if they find themselves having a nap in the afternoon, that's okay." TS 13:51 "What I find with these patients in particular is that a lot of times, their first symptoms related to any type of cancer are CNS symptoms from brain metastasis. Our patients with lung cancer or melanoma—they come in through the emergency room for altered mental status or seizures or something like that. They find a mass in their brain, and then they find a mass on their lung, or they find masses everywhere. Typically, they want to treat the brain masses first before they start them on any kind of systemic treatment. And so, they'll come to us, and they're in shock. Everything's happened very quickly. They haven't had a chance to really catch their breath. They're overwhelmed. And so I try to make sure they understand that everyone that they see here is part of their team and is with them through this journey and they're not alone." TS 25:36 "A couple of years ago, ONS put out an email asking for people to volunteer to do a delineation study about the feasibility of doing a radiation oncology certified nursing exam. And I, just on a whim, responded to that email. It's not something I've ever done before, and thinking that I would not be put on the team. … And I thought, 'I don't have enough experience, I don't know what I'm doing, and they won't choose me.' And lo and behold, they put me on this role delineation study. … I have met so many incredible nurses with all kinds of experience. I've learned so much. It has opened up a lot of things for me and it's been really exciting, so all I can do is say take advantage of those opportunities when they come. Don't think that you don't know enough, because you know more than you think you do." TS 32:38 

Episode 147 – Guanfacine   Welcome to the second in a little duo of episodes on oral alpha 2 agonists. In last week's episode (146), I spoke about clonidine, and this week, I'll be talking about guanfacine, comparing and contrasting the 2 for you in terms of use and indications. Guanfacine is a really useful psychopharmacological agent that is probably less commonly used than clonidine at this time, but I'm hoping this episode will give you a little more confidence to consider it for your patients.   Here's what I think you, as professionals, need to know about this medication.   Here's what you'll learn: ·         Indications for and uses of guanfacine as a daily adjunctive medication in Veterinary Behaviour Medicine. ·         Why guanfacine might be a good choice for hyper-aroused, hyper-active and hyper-vigilant patients. ·         When guanfacine might be a better choice than clonidine. ·         Potential drug interactions and contraindications.     This is a bit of a whistlestop tour into guanfacine, but if you'd like to dive even deeper, I've got you covered – My PSYCHOACTIVE course contains everything you need to know: https://katrin-jahn.mykajabi.com/psychoactive   And here is the link to my monthly membership – The Behaviour Case Collective – which I also mention in this episode: https://katrin-jahn.mykajabi.com/behaviour-case-collective   If you liked this episode of the show, Veterinary Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe!   Facebook Group: Join The Veterinary Behaviour Community on Facebook   You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn   Thank you for tuning in!

Interview with Brian S. Zuckerbraun, MD, MBA, author of Nasogastric Tubes—Indications, Placement, and Management: A Review. Hosted by Jamie Coleman, MD. Related Content: Nasogastric Tubes—Indications, Placement, and Management

Interview with Brian S. Zuckerbraun, MD, MBA, author of Nasogastric Tubes—Indications, Placement, and Management: A Review. Hosted by Jamie Coleman, MD. Related Content: Nasogastric Tubes—Indications, Placement, and Management

Episode 146 – Clonidine   Welcome to the first in a little duo of episodes on oral alpha 2 agonists. This week, I'll be talking about clonidine, and next week, I'm going to talk about guanfacine – another oral alpha 2 agonist – and compare and contrast the 2 for you in terms of use and indications. Clonidine is a really useful psychopharmacological agent that is quite commonly used as both an event medication as well as a daily adjunct to baseline medications.   So, I thought we'd do a bit of a deep dive into clonidine and the things you, as professionals, need to know about this medication.   Here's what you'll learn: ·         Indications for and uses of clonidine as both an event- and a daily adjunctive medication in Veterinary Behaviour Medicine. ·         Why clonidine might be a good choice for hyper-aroused, hyper-active and hyper-vigilant patients. ·         When clonidine might be a better choice than guanfacine. ·         Potential drug interactions and contraindications.   Here are the 2 published papers I mention in the episode: Ogata, N. and Dodman, N.H., 2011. The use of clonidine in the treatment of fear-based behavior problems in dogs: an open trial. Journal of Veterinary Behavior, 6(2), pp.130-137.   Pflaum, K., Albright, J., Cox, S. and Smith, J., 2026. Pharmacokinetics of Orally Administered Clonidine in Dogs. Journal of Veterinary Pharmacology and Therapeutics.   This is a bit of a whistlestop tour into clonidine, but if you'd like to dive even deeper, I've got you covered – My PSYCHOACTIVE course contains everything you need to know: https://katrin-jahn.mykajabi.com/psychoactive   And here is the Professional Guides E-Book I mention in the episode, which includes a handout about clonidine: https://katrin-jahn.mykajabi.com/trinity-ebook   If you liked this episode of the show, Veterinary Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe!   Facebook Group: Join The Veterinary Behaviour Community on Facebook   You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn   Thank you for tuning in!

Can a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Johnson & Johnson https://www.inlexzohcp.com/ --- Timestamps 00:00 - Introduction02:40 - Why Focus on TAR-20005:35 - Device Basics07:05 - Dosing Schedule Explained11:17 - SUNRISE-01 Trial Results15:07 - Patient Selection and Contraindications20:52 - Indications for Device Removal23:26 - Clinic Workflow Learning Curve25:56 - Tips for Insertion and Device Deployment28:52 - Cystoscopy Findings and Surveillance Protocol32:16 - Treatment Sequencing38:43 - Future Trial and Research Directions45:16 - Biomarkers, AI, and Personalizing Care46:35 - Cost, Supportive Care, and Patient Burden48:42 - Closing Thoughts --- More about this episode The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr. Psutka discusses dosing schedules, when to remove the device, and how to handle complications like UTI, hematuria, and LUTS. The episode also covers surveillance protocols, the impact on clinic operations, and the importance of balancing vigilant cancer surveillance with patient burden. Finally, they touch on future directions, including biomarkers, AI-assisted pathology, and optimizing the timing of cystectomy and supportive care for a more personalized approach to NMIBC. --- Resources TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Studyhttps://ascopubs.org/doi/10.1200/JCO-25-01651 SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-mushttps://www.urotoday.com/conference-highlights/suo-2024/suo-2024-bladder-cancer/156723-suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared-with-intravesical-chemotherapy-after-bacillus-calmette-guerin-in-recurrent-high-risk-non-muscle-invasive-bladder-cancer.htmlcle Invasive Bladder Cancer Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Resultshttps://ascopubs.org/doi/10.1200/JCO-25-02382 INLEXZO - SunRISe-3 Studyhttps://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-3-study --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In this conversation, Dr. Sammy Noumbissi discusses his journey into the world of zirconia implants, sharing insights on the differences between zirconia and titanium implants, patient preferences, and the importance of understanding the materials used in dental implants. He emphasizes the need for meticulous planning and the health of the recipient when using zirconia implants, as well as addressing common misconceptions about corrosion and implant materials. In this enlightening conversation, Dr. Sanda Moldovan and Dr. Sammy Noumbissi DDS MS delve into the world of ceramic implants, discussing their advantages over traditional titanium implants, the importance of material science, and the evolving technology in implantology. They explore the clinical observations regarding peri-implantitis, fracture rates, and the significance of patient health optimization. The discussion emphasizes the need for dentists to adapt to the growing demand for ceramic implants and the importance of thorough education and training in this field. Want to see more of The Holistic Dentistry Show? Watch our episodes on YouTube! Do you have a mouth- or body-related question for Dr. Sanda? Send her a message on Instagram! Remember, you're not healthy until your mouth is healthy. So take care of it in the most natural way.  Key Takeaways: (12:06) Understanding Zirconia vs. Titanium Implants (20:06) Patient Perspectives on Implant Choices (23:09) Corrosion and Material Considerations (23:45) Understanding Peri-implantitis and Ceramic Implants (26:40) The Material Science of Zirconia vs Titanium (29:40) Indications for Ceramic Implants (32:55) Advancements in Ceramic Implant Technology (37:49) Fracture Rates and Clinical Observations (40:42) Occlusion Adjustments for Ceramic Implants (45:47) Learning and Adapting to Ceramic Implants (51:41) The Importance of Patient Health Optimization (56:47) Future of Ceramic Implantology Connect with Dr. Sammy Noumbissi: Instagram: @sammynoumbissi and @iaoci_ceramicimplants Facebook: https://www.facebook.com/sammy.noumbissi and https://www.facebook.com/IAOCI/ Linkedin: www.linkedin.com/in/ceramicimplantdentist Dental professionals interested in advancing their knowledge of ceramic implantology are invited to attend the 2026 International Academy of Ceramic Implantology Annual Congress. The event will also celebrate the IAOCI's 15th anniversary and will take place September 10–12, 2026, in Chantilly, Virginia, near Washington, D.C. Early-bird registration is $525 through August 31, 2026. After August 31, registration increases to $675. For more information about the Annual Congress and other IAOCI events, visit https://www.iaoci.com/events/ Connect With Us:  AskDrSanda | YouTube BeverlyHillsDentalHealth.com | Instagram  DrSandaMoldovan.com | Instagram  Orasana.com | Instagram Integrative Dental Health Institute  | Ozone in Dentistry Course

“'You said that He is indeed everywhere, so why can He not be seen in this pillar? If I do see that Vishnu right now in the middle of the pillar, then I will not kill you. Otherwise, you will be divided into two.' Having seen (his father) in that way, Prahlada began to meditate on that Supreme Lord.” (Narasimha Purana, 44.10-11)

Contributor; Taylor Lynch, MD Educational Pearls: Thoracotomy  Thoracotomy is used in traumatic cardiac arrest to replace conventional CPR with direct access to the chest. Goals include identifying and controlling reversible causes of bleeding, prioritizing blood flow to the heart and brain, and performing open cardiac massage. Trauma categories Penetrating trauma: Gunshot wounds and stab wounds. Has a higher chance of survival because the injury may be localized and directly repairable. Cardiac stab wounds may have the highest survivability because the defect can be visualized, repaired, and treated with blood administration. Blunt trauma: Motor vehicle collisions and falls from height. Has a much lower chance of survival. Western guidelines EMS must witness the patient lose pulses. Penetrating trauma: CPR for less than 15 minutes. Blunt trauma: CPR for less than 10 minutes. Survival decreases to essentially zero beyond these time limits. Eastern guidelines Focus on the presence of signs of life in blunt or penetrating trauma. Signs of life may include: Pupillary response. Measurable blood pressure. Purposeful movement. Patient selection Thoracotomy should only be performed when the patient has a reasonable chance of survival. It is a highly morbid procedure with significant occupational risks, including needlestick injury. Appropriate patient selection and timing are essential. Procedure Begin on the left side of the chest. Cross-clamp the aorta to restrict blood flow below the heart and prioritize circulation to the heart and brain. Identify and repair visible sources of bleeding involving structures such as the heart or lungs. Perform open cardiac massage as the equivalent of CPR. ACLS medications may still be administered. References: Cothren CC, Moore EE. Emergency department thoracotomy for the critically injured patient: Objectives, indications, and outcomes. World J Emerg Surg. 2006;1:4. Published 2006 Mar 24. doi:10.1186/1749-7922-1-4 Rhee, Peter M. ; Acosta, Jose ; Bridgeman, Amy et al. / Survival after emergency department thoracotomy : Review of published data from the past 25 years. In: Journal of the American College of Surgeons. 2000 ; Vol. 190, No. 3. pp. 288-298. Nunn, Andrew ; Prakash, Priya ; Inaba, Kenji et al. / Occupational exposure during emergency department thoracotomy : A prospective, multi-institution study. In: Journal of Trauma and Acute Care Surgery. 2018 ; Vol. 85, No. 1. pp. 78-84. Burlew CC, Moore EE, Moore FA, et al. Western Trauma Association critical decisions in trauma: resuscitative thoracotomy. J Trauma Acute Care Surg. 2012;73(6):1359-1363. doi:10.1097/TA.0b013e318270d2df Seamon MJ, Haut ER, Van Arendonk K, et al. An evidence-based approach to patient selection for emergency department thoracotomy: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2015;79(1):159-173. doi:10.1097/TA.0000000000000648 Summarized by Steven Fujaros NREMT | Edited by Steven Fujaros & Ahmed Abdel-Hafiz, NREMT-P   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf

Have you considered performing a cochlear implant while your patient is awake? In this episode of the Backtable ENT & Allergy Podcast, Dr. Walter Kutz and Dr. Brandon Isaacson sit down with Dr. Sarah Mowry to explore her protocol for cochlear implants under local anesthesia, an approach especially relevant for older adults concerned about the cognitive risks of general anesthesia. Dr. Mowry shares her criteria for patient selection, preoperative counseling strategies, and how she adapts the OR setup to maximize comfort and communication during awake surgery. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:06 - Why to Consider Awake Cochlear Implants05:32 - Indications for Awake CI 08:50 - Local Blocks and Pain Control10:58 - Counseling and Expectations14:40 - Preventing Intraoperative Vertigo and Converting to General Anesthesia 17:17 - Set Up and Communication with Patient 19:14 - Lesser Occipital Nerve Block and Potential Role of Processed EEG26:32 - Pitch Matching for Single-Sided Deafness, CI, and Anxiety Considerations29:00 - Feedback from Patients and Electrode Choice 31:30 - Advice to Surgeons and Closing Remarks --- More about this episode The conversation covers her anesthesia protocol, including lesser occipital and postauricular nerve blocks, minimizing propofol, and using topical 2% lidocaine in sensate areas like the facial recess and epitympanum. Dr. Mowry discusses practical strategies of using warmed irrigation to reduce intraoperative vertigo and contingency plans for conversion to general anesthesia. She discusses electrode considerations and the potential role of processed EEG to titrate anesthesia depth and practical tips for surgeons interested in adopting awake cochlear implantation. Throughout, they highlight the importance of individualized patient care, multidisciplinary teamwork, and the growing role of local anesthesia in otologic surgery. --- Resources Cochlear Implantation Under Local Anesthesia With Conscious Sedation in the Elderly: First 100 Caseshttps://pubmed.ncbi.nlm.nih.gov/32663339/ Cochlear implantation under local anesthesia in 117 cases: patients' subjective experience and outcomeshttps://pubmed.ncbi.nlm.nih.gov/34487218/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Format Change for the Parks Panel at D23-  Disney has announced that Neil Patrick Harris will be the host for the Experiences Showcase at D23 2026 next month- Indications are this will build on what was announced in 2024 rather than be a bunch of new announcements. We discuss the implications of thisSource: WDW MagicStarts @ ...RUMOR: Space Mountain Redo-  Lots of chatter that the next ride to have an update at Walt Disney World will be Space Mountain - but will it just be a refresh or something more extreme?- Would we plan a special trip to ride it one last time? When do we think the ride will go down for this update?Starts @ ...Jason's Trip Report:-  Jason is just back from 8 days at Walt Disney World. He has thoughts on: The resorts he stayed at, the Quick Service Dining Plan, Diet EPCOT, all the new things there, and more!Starts @ ...This was episode 314 for the week of July 13, 2026* Reminder to like, subscribe, rate, and review the DBC Pod wherever you get your podcast *Send us an e-mail! .... thedbcpodcast@gmail.comFollow us on social media:- LinkTree: https://linktr.ee/thedbcpod - Bluesky: @thedbcpod.bsky.social- Instagram: https://www.instagram.com/TheDBCPod/- Twitter: https://twitter.com/TheDBCPod- Facebook: https://www.facebook.com/TheDBCPod- YouTube Channel: https://www.youtube.com/thedbcpod- Discord Server: https://discord.com/invite/cJ8Vxf4BmQNote: This podcast is not affiliated with any message boards, blogs, news sites, or other podcasts

Another conversation with Dr. Alex Khalessi Find the video of this conversation at https://youtu.be/alfpNjdrXkw

Want to know your English level? Take our free English-level quiz here to find out what your current English level is.  Do you love All Ears English?  Try our other podcasts here: Business English Podcast: Improve your Business English with 3 episodes per week, featuring Lindsay, Michelle, and Aubrey IELTS Energy Podcast: Learn IELTS from a former Examiner and achieve your Band 7 or higher, featuring Lindsay McMahon and Aubrey Carter with Jessica Beck in previous episodes Visit our website here or https://lnk.to/website-sn If you love this podcast, hit the follow button now so that you don't miss five fresh and fun episodes every single week.  Don't forget to leave us a review wherever you listen to the show. Send your English question or episode topic idea to support@allearsenglish.com Shopify: Stop waiting for permission to build something. Your next revenue stream starts free at shopify.com/aee Learn more about your ad choices. Visit podcastchoices.com/adchoices

Curtis Harding ger oss soulmusikens gemensamma medvetande på ett moln av rymdstoft. Längtan, smärta, kamp och ett artisteri som kopplas till drömmens logik. Lyssna på alla avsnitt i Sveriges Radios app. Vad är skillnaden mellan så kallad retrosoul och AI-musiken som bygger på något gammalt? Förutom ett mindre generiskt låtskrivande är det förmodligen ett artisteri som ser på historien med nya ögon. Curtis från Saginaw, Michigan visar sambandet mellan då och nu och lyckas få klassisk soul att kännas angelägen, till och med modern. Mats Nileskär möter även hans syskonsjälar Leon Bridges och Durand Jones & The Indications.I timme två likaså i sommar Sverigeaktuelle Jalen Ngonda som föddes drygt en halvtimme från sjukhuset i Washington DC där hans idol Marvin Gaye kom till världen 55 år tidigare. Äldre musik fick den unge Jalens blod att rusa. 11-åringen upptäckte det historiska skivbolaget Motown och vägen var utstakad. Mats träffar även Temptations David Ruffin och Eddie Kendricks.

For years, an indeterminate thyroid biopsy meant diagnostic surgery but molecular testing is now changing that reality entirely. On this episode of the BackTable ENT podcast, Dr. Ashley Agan interviews endocrinologist Dr. Erik Alexander about how molecular testing and a systematic, layered approach to thyroid nodule evaluation are reducing diagnostic surgeries and enabling more individualized patient care. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Veracytehttps://www.veracyte.com/ --- Timestamps 00:00 - Introduction02:48 - Incidence, Presentation, and Workup of Thyroid Nodules 06:26 - Hormonal Impact and Indications for FNA 10:49 - FNA workflow and Bethesda Categories 16:10 - Role of Molecular Testing for Indeterminate Nodules19:59 - Evolution of Molecular Testing and Afirma 23:51 - Basics of DNA based Testing and RNA based Testing 28:34 - Comparing DNA based and RNA Based Testing 32:10 - Utility of Molecular Testing and Sampling Techniques 35:55 - Cost Coverage and Practical Limits39:20 - Clinical Implications and Future Impact42:00 - Final Takeaways --- More about this episode Together they walk through the full evaluation pathway, including ultrasound risk stratification using the TI-RADS criteria, the role of TSH testing, and how FNA indications have shifted from biopsying every solid nodule to a more selective, risk-adapted approach. The discussion covers the Bethesda classification system and addresses why the one-third of patients landing in indeterminate categories (Bethesda III, IV, and V) have historically been the most challenging and most overtreated group. The conversation then explores molecular diagnostics as an additional layer of risk assessment, highlighting key differences between DNA-based mutation panels and RNA-based expression classifiers. Dr. Alexander also discusses practical considerations like insurance coverage, sampling technique, turnaround time, and the future potential of molecular testing to move beyond diagnosis toward individualized prognosis. --- Resources American College of Radiology: TI-Rads Guidelines https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/RADS/TI-RADS/TI-RADS-Assessment-Categories.pdf American Thyroid Association - Nodule Guidelineshttps://pmc.ncbi.nlm.nih.gov/articles/PMC4739132/ Bethesda System for Reporting Thyroid Ctyopathology https://www.ncbi.nlm.nih.gov/books/NBK278969/table/thyroid-nod-canc-eld.T.bethesda_system_f/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

本期节目我们一起来品鉴被誉为“水果界淡人”的莲雾，一种小众但今年有点“红了”的水果。如果不是生活在海南、广东、广西或福建，莲雾对大多数朋友来说挺陌生的，很少吃，第一次尝试好像都会觉得寡淡，水分多但一点都不甜，甚至带着不愉悦的涩味。但我们这次买到了很好吃的莲雾，甜度比一般的要高，破除了一些刻板印象，还挺惊喜的。另外顺手买了水蒲桃（正式名为“蒲桃”），与莲雾同为桃金娘科蒲桃属的另一种水果，构造和香气很奇特，越吃越喜欢。01:51 莲雾到现在都是非常小众的水果，有些品种太难买了03:30 网购“滑铁卢”，翡翠莲雾迟迟不发货07:02 另辟蹊径想买南鹿一号莲雾，结果没赶上录节目09:16 海南黑金刚莲雾切开水汪汪的，清甜得像梨13:00 有人曾经吃到过非常涩的莲雾（随手摘的）15:08 泰国老品种红宝石，是印象中莲雾的味道，含糖量低、水分足19:23 莲雾最近为什么“红了”？有啥健康属性？21:55 水蒲桃长得挺有风骨（鼓），越闻越像新鲜玫瑰25:10 莲雾、蒲桃为什么和桉树一样有挥发性香气？29:57 从东南亚到台湾、泉州、两广、海南，莲雾像一艘船36:03 有一些意想不到的植物都属于桃金娘科，包括桉树42:52 想起电影《给阿嫲的情书》和书《燕食记》里都有莲雾47:52 回复评论：什么时候斥巨资品鉴榴莲呢？片头BGM：Men I Trust - Seven片尾曲：Durand Jones & The Indications,Aaron Frazer - Flower Moon【本期主播】秋蓬｜House｜乐克｜郭爱美【收听与联络方式】欢迎大家在苹果播客、小宇宙App、Spotify、喜马拉雅、荔枝App、网易云音乐、QQ音乐等音频平台订阅本节目。如有反馈或合作需求，请发邮件至289004133@qq.com，大家也可以在新浪微博搜索「鲸鱼赫兹」找到我们。还可以关注我们的小红书账号“鲸鱼赫兹NEVERLAND”，会发些节目外的事情。

Text comments and questions here!This month feels like the beginning of summer. I know we're not quite there based on the calendar. I don't care! It feels like summer to me, and I'm sure it's because I took a little vacation. Travel along with me to Scottsdale, Arizona. It was an adventure! Laughing Matters features the end-of-the-month highlights and usually includes four segments: celebrations, libation of the month, rants, and questions and answers. Celebrations are about intentionally forming a habit of noticing and acknowledging the good within and around you. Libation of the month is based on whatever I fancy or feel inspired by at the time. I share step-by-step instructions and you can mix right along with me. Rants or stories are about anything I find funny and want to share. Ask me a question. It might be featured in a future episode.Libation of the Month:Spiked Matcha LatteRecipe from sakeone.com2 tsp Matcha Powder1 oz Hot Water6 oz Milk (Non-Dairy for me)1 oz Simple Syrup1.5 oz SakeSprinkle with Matcha PowderServe in a big coffee cup (glass if possible)Add a fun strawMentions: The Scott Resort and Spa“The Way That I Do” by Durand Jones & The Indications & Aaron FrazerConnect with Me: Subscribe * Follow * Rate * CommentSee me on Instagram Reach out on Bluesky @laughingnotesEmail me at laughsandlibs@gmail.comVisit laughterandlibations.com

Routine doesn't mean risk-free. What should be considered before, during, and after inferior vena cava (IVC) filter placement? In this episode of the BackTable Podcast, interventional radiologist Dr. Daniel O'Neal (Ohio State University) joins guest host Dr. Jessica Yoon to walk through the workup protocols, technical considerations, and multidisciplinary approaches required for placing and following up on IVC filters. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by RADPAD® Radiation Protectionhttps://www.radpad.com/ --- Timestamps 00:00 - Introduction02:10 - IVC Filter Basics07:37 - Workup and Contraindications12:18 - Pre-Procedural Imaging and Timing14:35 - Procedural Technique18:53 - Cavagram and Variant Anatomy23:18 - Filter Positioning and Deployment30:02 - IVC Filter Complications33:58 - Post-Placement Follow-Up39:14 - Final Thoughts and Closing Remarks --- More about this episode The physicians review the key indications for the procedure, highlighting evidence-based patient selection and emphasizing the need for interventional radiologists to critically assess the clinical workup rather than function merely as technicians. They discuss how a comprehensive pre-procedural workup relies on cross-sectional imaging to identify access obstacles and to plan for adequate filter placement in cases of variant anatomy. Dr. O'Neal also shares technical tips from the suite, including deployment mechanics, positioning considerations, and strategies for preventing common complications. The conversation concludes with the IR's ongoing responsibility to ensure a robust, multidisciplinary follow-up system with referring specialties, outlining potential strategies to ensure these devices are safely retrieved in a timely manner when no longer indicated. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

BiTEs or bispecific T-cell engager antibodies are an emerging class of therapies with significant potential to advance cancer treatment. Pharmacists will play a key role both in the utilization of these agents but also in the mitigation and management of the unique toxicities that accompany them. This podcast provides insights into the patient care needs and novel interdisciplinary models employed to support patients receiving BiTE therapies. Listeners will gain key insights into BiTE therapies, including their role in treatment, the current pipeline, and safety considerations. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

On today's show Andrew and Bill begin with the news that Beijing moved to further ease hukou restrictions, including why this is a welcome change for millions of Chinese citizens, as well as a look at questions and challenges as the reforms are implemented. Then: A report that Chinese AI talent has been restricted from leaving China, while Beijing continues its efforts to control capital outflow and offshore investments. From there: Indications that the US has indeed paused its second tranche of arms sales to Taiwan, and more details on a US-China board of investment. Then: PRC-Japan updates, including reports of Takaichi recriminations from Xi in his meeting with Trump, heavy rare earth shipments restricted for the past four months, the cards Japan has yet to play, and Mao's strategic stalemate as a stage of protracted war, not an endgame. At the end: An American journalist for Xinhua and other state outlets is arrested and accused of acting as an unregistered agent of the CCP.

"When you have benign conditions, we're actually treating 3 gray, so a significant difference [versus doses of 60 gray for brain cancer]. Typically, when you treat at a high dose, the goal is to destroy tissue, like cancer tissue or cancer cells. But when we give a low dose, the goal is actually to modulate inflammation. And what it does is it slows down those inflammatory cells or those cells that release the chemicals that cause pain and inflammation," Amanda Meyer, DNP, APRN, CNP, family nurse practitioner in the Department of Radiation Oncology at the Mayo Clinic in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation therapy for noncancer indications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 22, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of radiation to treat noncancerous conditions. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Quick Quiz: Test Your Knowledge of Radiation Care Coordination ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS Radiation Oncology Conference Recordings Bundle™ ONS ROCN™ Certification Review™ Radiation Oncology 101: 2024 ONS Bridge™ Session ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Findings From the 2023 Radiation Oncology Nursing Role Delineation Study to Shape the Future of the Subspecialty The Role of Advanced Practice Providers in Radiation Oncology in 2025 ONS Huddle Cards: Radiation Radiobiology German Society for Radiation Oncology (DEGRO): Guidelines in Radiotherapy: Radiotherapy for Benign Diseases To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We always typically think of it as cancer treatment, but we can use radiation for noncancerous conditions, as well. And radiation was actually used for benign diseases right after the discovery of x-rays. By the 1920s it was used a lot for different types of musculoskeletal, dermatologic issues, and different types of inflammatory conditions. And over time, since the 1920s, we've actually really gotten a really good understanding of it." TS 1:37 "When we're looking at what are good candidate characteristics, we do typically like older patients, so patients over the age of 65. And the rationale behind that is we know that there is a potential for a secondary risk of a skin cancer about 20 to 30 years after getting low-dose radiation, like a basal cell or squamous cell skin cancer. The older the patient is, the less likely they are to have any adverse effects from that." TS 8:22 "When we do the low-dose radiation, they've tried other measures that haven't been successful. However, we don't want a patient who is so severe that they're ready for surgery, when they're bone on bone, because we know that radiation isn't as effective when they are that severe. So there's this sweet window where low-dose radiation works best in these patients." TS 9:39 "When we're treating with a little bit higher dose for like a Dupuytren's or a Ledderhose, because it's an anti-proliferative dose, those patients, they do get more skin redness, more dry skin. That's very temporary, and it resolves within a week or two after treatment. But really, we don't see any acute side effects. The long-term side effect of the radiation-induced malignancy, again, is a very low—0.05% according to some of the European guidelines." TS 12:34 "I really wish people appreciated how interdisciplinary this is. We need to get referrals from family medicine and from primary care and internal medicine and pain medicine physicians and inflammatory physicians and podiatry and pain specialists. And we really need to use this multidisciplinary approach to get earlier referrals for patients because there is this sweet window of time where low-dose radiation works the best." TS 18:40

For review:1. CIA Director Ratcliffe met with counterparts from Cuba's Ministry of the Interior on Thursday during a high-level visit to the island nation amid "complex bilateral relations" between the long-time adversaries.2. President Donald Trump says he has not yet decided whether a major sale of US arms to Taiwan can move forward following his three-day visit to China. 3. Israel said that it had targeted Izz al-Din al-Haddad, the Hamas leader in the Gaza Strip and the head of the terror group's military wing, in an airstrike in Gaza City on Friday.  A senior Israeli security official told reporters that were “initial indications” that Haddad was killed.  The IDF has not yet officially commented on the strike.4. US President Donald Trump counted “the military decimation of Iran” among his administration's accomplishments in a social media post on Thursday, adding, “to be continued!”The phrase, included in a lengthy Truth Social Post suggested he may resume the war against Iran after he returns from his trip to China on Friday. 5. US President Donald Trump said Friday that he would accept a 20-year suspension of the uranium enrichment at the heart of Iran's rogue nuclear program if Tehran gave a “real” guarantee, in an apparent shift from his previous demand that Iran permanently halt its program and his pledge to ensure Iran can never attain nuclear weapons.6. US CENTCOM CDR Admiral Brad Cooper appears at SASC Hearing. Admiral Cooper:- US has the military power to permanently reopen the Strait of Hormuz.- Iran's ability to threaten its neighbors and US interests has been dramatically reduced by US bombings, and Tehran's defense industry has been set back by 90%.- Iran was no longer able to transfer arms and other resources to its main allies in the region: Hezbollah in Lebanon, the Houthis in Yemen and Hamas in Gaza. “Those transfer paths and methods have been cut off.”7. The United States on Friday announced a 45-day extension of a porous ceasefire between Israel and Hezbollah in Lebanon, even as the Iran-backed terror group continued to clash with IDF soldiers and launch missiles and drones into Israeli territory.8. Palestinian Authority President Mahmoud Abbas's Fatah party on Thursday began a three-day conference to elect its highest leadership body for the first time in 10 years.

Why are some GJ tubes more prone to failure, and what can you actually do about it? In this episode of the BackTable Podcast, Dr. Chris Beck hosts Dr. Kevin Wong, a pediatric interventional radiologist at the University of South Alabama, to discuss the complexities of gastrojejunostomy (GJ) tube management in hospital-based IR, especially in pediatric patients. The discussion offers clinically relevant guidance on troubleshooting, device selection, and multidisciplinary approaches to enhance GJ tube care and improve patient outcomes. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction05:40 - Etiologies of GJ Tube Dislodgement and Placement Considerations 12:17 - Spiral Upsizing Solutions14:30 - Parent Education Playbook19:34 - Indications for GJ Conversion21:55 - Criteria for GJ Removal24:12 - Preferred Low-Profile Tube Designs27:15 - Addressing Suboptimal Angles and Guidewire Selection31:26 - Strategies to Prevent Tube Occlusion33:34 - Wish List for Industry 36:12 - Balloon Assisted Placement Techniques37:58 - Wrap Up and Credits --- More about this episode The doctors explore why GJ tubes fail and how to manage common complications, such as balloon failures, vomiting-induced dislodgement, stoma enlargement, and recurrent malfunction due to poor gastrostomy angle or architecture, often seen with surgically placed G-tubes. Dr. Wong shares prevention strategies, including parent education on balloon-volume checks and refills, sending patients home with a backup G-tube, minimizing upsizing, and addressing traction and granulation tissue (including the use of silver nitrate). He also covers approaches to clog management such as warm water, Coke, aggressive flushing, and avoiding routing medications through the G port. The episode wraps up with a discussion on device preferences (AMT G-JET versus MIC-KEY), tips for wire and catheter exchanges, and the need for industry improvements in materials and lumen design. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

In this episode, Dr. Saraswat and Dr. Kocak dive into the latest advancements in breast augmentation, focusing on the innovative Motiva implants by Preservé. They discuss how these new tools are changing the landscape of breast surgery, offering patients more options with faster recovery times and improved outcomes. Overview of Motiva implants and their nano-textured surface Benefits of nanotexturing in reducing inflammatory response Comparison with other textured and smooth implants Indications for subglandular versus submuscular placement Specific surgical techniques, including under-dissecting and hybrid augmentation The Preservé Motiva approach to maintaining breast architecture Ideal candidates for Preservé Motiva and targeted augmentation Potential for faster recovery and minimal downtime Long-term outcomes and patient satisfaction Future perspectives on breast augmentation innovation Connect With Midwest Breast https://mwbreast.com/ https://www.instagram.com/mwbreast/  

Episode 134 – Escitalopram   Escitalopram is a really useful SSRI that is quite commonly prescribed by Veterinary Behaviour Specialists or veterinarians with a strong interest in Behaviour Medicine but is possibly sometimes overlooked by general practitioners. So, I thought we'd do a bit of a deep dive into escitalopram and the things you, as professionals, need to know about this medication.   Here's what you'll learn: ·         Indications for and uses of escitalopram in Veterinary Medicine ·         Why escitalopram might be a good choice for fearful and anxious patients ·         When Escitalopram might be a better choice than fluoxetine (if legally possible – the dreaded cascade !!). ·         Potential drug interactions and contraindications.   This is a bit of a whistlestop tour into escitalopram, but if you'd like to dive even deeper, I've got you covered – My PSYCHOACTIVE course contains everything you need to know: https://katrin-jahn.mykajabi.com/psychoactive   And, if you'd like to learn how escitalopram and other Veterinary Psychopharmaceuticals can be applied practically, then The Behaviour Case Collective, where we take a deep-dive into one real-life Behaviour Case every month, might be just the thing for you! https://katrin-jahn.mykajabi.com/behaviour-case-collective   If you'd like to book a 30-minute Vet-Vet or Vet-Pet Care Professional Consultation with me, you can do that right here: https://calendly.com/trinityvet/teams-and-professionals If you can't find an appointment time to suit you, please email us at info@trinityvetbehaviour.com to find a time that suits us both!   And if you'd like some amazing E-Books including Client Handouts and Professional Guides, then have a look here: https://katrin-jahn.mykajabi.com/trinity-ebook   If you liked this episode of the show, Veterinary Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe!   Facebook Group: Join The Veterinary Behaviour Community on Facebook   You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn   Thank you for tuning in!

AMERICA'S SUPPLY CHAIN ON THE BRINK: HIDDEN THREATS YOU CAN'T IGNORE - On this intense episode of Rural Route, host Trent Loos is joined by JC Cole from New Jersey for a hard-hitting breakdown of the growing dangers facing America's supply chain. JC unveils a powerful SWOT analysis identifying 13 looming “gray swan” events—serious threats that could trigger a nationwide collapse. From seismic activity along the New Madrid fault to rising concerns about solar EMP attacks, the conversation exposes just how fragile the system has become. The discussion dives deep into global instability, including fears of economic collapse, digital currency shifts, and escalating geopolitical tensions that could disrupt trade overnight. Trent and JC warn that years of ignored warnings may be creating dangerous complacency, even as risks intensify across the board. Turning to solutions, JC pushes for bold action—calling for localized food production and small-scale farming systems to protect communities, especially along the vulnerable East Coast. With reports of farm bankruptcies surging and fertilizer prices crushing producers, Trent highlights the growing pressure on American agriculture and the real threat of food shortages. The episode closes with a gripping look at gold and silver markets, questions surrounding U.S. reserves, and how global financial uncertainty ties directly into food security and survival. It's a powerful wake-up call about the future of farming, national security, and the fight to keep America fed.

Contributor: Alec Coston, MD Educational Pearls: What are nasal intubations and when do we use them? Nasal intubations function similarly to oral intubations with the end goal of passing an endotracheal tube (ETT) through vocal cords and into the trachea to allow for a patent and secure airway, but differ in the main access point for the ETT (nare v.s. mouth). Nasal Intubations are seldom preferred to oral intubations as they carry risk for inducing bleeding from trauma to the nasal passages.  Indications for nasal intubations include: Anatomical abnormalities that may make access through the mouth difficult (i.e. tumors, macroglossia, or rare dental hardware that clenches the jaw shut). Physiological states such as severe angioedema.  Nasal intubations are often done with the patient awake and could be advantageous if the patient is presenting in a severely hypoxic state such that prolonged hypoxia in a traditional RSI protocol may be detrimental. A 2023 retrospective analysis in Germany found that nasal intubations were associated with requiring less sedation than oral intubations and had more spontaneous breathing during hospitalization than oral intubations. How is a nasal intubation performed? Consider the use of an anxiolytic medication such as versed to calm the patient down but not fully sedate them. If there is adequate time without immediate patient compromise, consider glycopyrrolate to reduce airway secretions and dry up the mucous membranes. Consider the use of Afrin or other local vasoconstrictor in target nare to minimize epistaxis.    Use 5% lidocaine ointment and lubricate an NPA and place it into the target nare. This will allow for local anesthesia as well as help to open up the nare slightly more.  Take 5% lidocaine ointment and place it on a tongue depressor and move it around the back of the tongue, allowing it to further anesthetize the oropharynx.  Remove the NPA and atomize/nebulize 4% lidocaine liquid into the nare and into the oropharynx for further anesthesia.  Insert the ETT without the bronchoscope through the nare and allow it to pass about 10 cm until visible in the oropharynx. This allows for a "clean" plastic tunnel to pass the bronchoscope through. Advance both the ETT and bronchoscope, spraying lidocaine through the bronchoscope while advancing to allow for continued numbing.  Pass the ETT through the cords and inflate.  At this point, stronger sedation medications such as ketamine and propofol may be considered but the use of a paralytic like succinylcholine and rocuronium may not be needed to allow the patient to maintain their own negative pressure ventilation.  Which nare is the best to go through? Most patients will have their right nare be the best (away from the septal deviation) according to a meta-analysis by Tan et al.  The right nare was generally associated with less epistaxis and lower intubation times.  However, do not always default to the right nare, and test which nare is more patent by occluding one nare at a time and assessing which one is less resonant  (less resonant = more patent).  Key Takeaway? Nasal intubations are rarer than oral intubations and can be more technically difficult, but may offer advantages in patients with difficult oral airways, but should never be first line.    References: Grensemann J, Gilmour S, Tariparast PA, Petzoldt M, Kluge S. Comparison of nasotracheal versus orotracheal intubation for sedation, assisted spontaneous breathing, mobilization, and outcome in critically ill patients: an exploratory retrospective analysis. Sci Rep. 2023;13:12616. doi:10.1038/s41598-023-39768-1 Tan YL, Wu ZH, Zhao BJ, Ni YH, Dong YC. For nasotracheal intubation, which nostril results in less epistaxis: right or left?: A systematic review and meta-analysis. Eur J Anaesthesiol. 2021;38(11):1180-1186. doi:10.1097/EJA.0000000000001462 Holzapfel L. Nasal vs oral intubation. Minerva Anestesiol. 2003;69(5):348-352.   Summarized by Dan Orbidan, OMS2 | Edited by Dan Orbidan & Ahmed Abdel-Hafiz, NREMT-P   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf

Episode 132 – Paroxetine   Paroxetine is a really useful SSRI that is quite commonly prescribed by Veterinary Behaviour Specialists or veterinarians with a strong interest in Behaviour Medicine but is possibly sometimes overlooked by general practitioners. So, I thought we'd do a bit of a deep dive into paroxetine and the things you, as professionals, need to know about this medication.   Here's what you'll learn: ·         Indications for and uses of paroxetine in Veterinary Medicine (and some super easy ways to remember them). ·         Why paroxetine might be a good choice for Canine Separation Related Behaviours ·         When paroxetine might be a better choice than fluoxetine (if legally possible – the dreaded cascade !!). ·         Potential drug interactions and contraindications.   This is a bit of a whistlestop tour into paroxetine but if you'd like to dive even deeper, I've got you covered – My PSYCHOACTIVE course contains everything you need to know: https://katrin-jahn.mykajabi.com/psychoactive   And, if you'd like to learn how paroxetine and other Veterinary Psychopharmaceuticals can be applied practically, then The Behaviour Case Collective, where we take a deep-dive into one real-life Behaviour Case every month, might be just the thing for you! https://katrin-jahn.mykajabi.com/behaviour-case-collective   If you'd like to book a 30-minute Vet-Vet or Vet-Pet Care Professional Consultation with me, you can do that right here: https://calendly.com/trinityvet/teams-and-professionals If you can't find an appointment time to suit you, please email us at info@trinityvetbehaviour.com to find a time that suits us both!   And if you'd like some amazing E-Books including Client Handouts and Professional Guides, then have a look here: https://katrin-jahn.mykajabi.com/trinity-ebook   If you liked this episode of the show, Veterinary Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe!   Facebook Group: Join The Veterinary Behaviour Community on Facebook   You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn   Thank you for tuning in!

Indications for the use of bispecific antibodies (BsAbs) are rapidly increasing in oncology. While many cancer centers are keeping an eye on this developing field, curiosity must be transformed into proactive planning to avoid being caught unprepared as BsAb indications expand. In this episode, CANCER BUZZ speaks with Laura Kuzma, MSW, admin administrative director of FirstHealth Cancer Center and Oncology Services at FirstHealth Moore Regional Hospital, about the real-world lessons she has learned about governance considerations, ramp-up strategies, and workflows. She shares the importance of proactively building workflows, readiness plans, and cross-team communication pathways to safely operationalize BsAb therapy. Guest: Laura Kuzma, MSW  Administrative Director, Oncology Services and Clinical Trials FirstHealth Moore Regional Hospital Pinehurst, NC "That was the biggest hesitancy: are we equipped to manage this type of care in this type of setting?" "My request to the hospital administrators was to allow me to put together a team across the hospital to fully explore the financial side as well as the medical management side." "We had doctors in every area of the hospital on this. They cared about it, and I think it was exciting to them too. They felt like they were doing something meaningful, and their input was taken seriously." Resources: A Blueprint for Successful Integration of Bispecific Antibodies  Delivery Models for Administering T-Cell-Engaging Bispecific Antibodies Deliverying T-Cell-Engaging Bispecific Antibodies: Frequently Asked Questions (FAQ) ACCC Office Hours Recording - Bispecific Antibodies: One BiTE at a Time    Bispecific Antibodies Checklist for Community Providers Using Bispecific Antibodies in Community Practice: Challenge and Opportunities Expanding Access to Cellular and Bispecific Therapies: Considerations and Recommendations  

Send us Fan MailProudly Produced by The Oncology NetworkProfessor Craig Underhill and Rachael Babin break down the key oncology changes from the April 2026 PBS update.This month we run through six fresh PBS listings and policy changes that affect Australian oncology and haematology practice, from ROS1-positive non small cell lung cancer to perioperative immunotherapy and late-line blood cancer options. We focus on who benefits, what the key trial signals are and what clinicians need to monitor so access translates into safe, real-world outcomes. Repotrectinib listed for ROS1-positive NSCLC, including activity after prior TKIs and in resistant mutations, plus monitoring for dizziness and pneumonitis Durvalumab listed for muscle-invasive bladder cancer using the Niagara perioperative regimen, balancing survival gains with immune-related toxicity Three new pembrolizumab listings across cervical cancer, adjuvant renal cell carcinoma and perioperative head and neck cancer, with discussion of endpoints and eligibility Haematology additions including a BCMA bispecific for relapsed myeloma, an oral kinase inhibitor for higher-risk myelofibrosis and mogamulizumab for cutaneous T-cell lymphoma PBS price cuts via generics and biosimilars, plus expanded supervised prescribing for some medicines by nurse practitionersFollow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals.Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

This podcast episode breaks down diabetes “compelling indications” in a way that's highly practical for nurses managing complex patients. It explains how comorbid conditions like cardiovascular disease, heart failure, and chronic kidney disease influence medication selection beyond just lowering A1c. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!

Live from the Arthrex Team Physician Controversies ConferenceIn this episode of The Sports Docs Podcast, Dr. Ashley Bassett and Dr. Catherine Logan sit down LIVE from the Arthrex Team Physician Controversies with two leading ACL experts—Dr. Pat Smith and Dr. Aaron Krych—to discuss strategies to reduce failure after ACL reconstruction.The conversation highlights the evolution of ACL surgery, focusing on graft selection, fixation, biologic augmentation, and mechanical protection, with an emphasis on optimizing outcomes in young, high-risk athletes.Graft: Autograft vs AllograftStrong evidence shows higher failure rates with allograft in young athletes MOON data: ~4–6x increased risk of failure in patients

Sur cet épisode de Le Sick Podcast, Martin Biron, Denis Gauthier et Jack Han se joignent à Tony Marinaro! En bonus, quelques extraits de l'entrevue entre Tony et Kent Hughes! Learn more about your ad choices. Visit megaphone.fm/adchoices

Albumin is one of those topics where everyone has an opinion, but very few people actually look at the cost-benefit data. In this lecture, I'm breaking down why the 5% albumin you're hanging might be a waste of money, and where the 25% concentration actually moves the needle in septic shock and cardiac surgery.In this episode, we cover: The "Cool" Science: Where does this stuff come from? (Cold Cohn Fractionation). The Price Tag: Why your hospital administrator cringes when you order it.Sepsis & Septic Shock: What the SAFE and ALBIOS trials actually showed vs. the "statistical gymnastics" used to find a benefit.Cardiac Surgery: Does it help the kidneys or hurt them? (Comparing ALBICS-AKI and HAS-FLAIR II). The Lasix Combo: Is there a real mortality benefit to the albumin-lasix "concoction"?Citations: All data points have PubMed IDs listed in the slides. Please read these for yourself. Disclaimer: This is for educational purposes only and is not medical advice. I'm an ICU physician, but I'm not your physician.Timestamps:0:00 Intro & Disclaimers 1:45 How Albumin is made (and why the glass bottles?) 4:30 Electrolyte breakdown: Sodium and Chloride concerns 6:00 The actual cost vs. Saline/LR 9:15 Why our patients' albumin levels drop in the first place 12:30 Sepsis survival: The statistical gymnastics 16:00 Septic Shock & 20% Albumin 19:00 Early Resuscitation: Should you wait 6 hours?22:30 Cardiac Surgery: The AKI controversy 26:15 Albumin & Lasix: Does it actually work? 29:00 Final Verdict: Is 5% Albumin dead?The Vasopressor & Inotrope HandbookAmazon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.to/47qJZe1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Affiliate Link)My Store: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eddyjoemd.myshopify.com/products/the-vasopressor-inotrope-handbook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Use "podcast" to save 10%)

Episode 129 – Sertraline   Sertraline is a really useful SSRI that is quite commonly prescribed by Veterinary Behaviour Specialists or veterinarians with a strong interest in Behaviour Medicine but is possibly sometimes overlooked by general practitioners. So, I thought we'd do a bit of a deep dive into sertraline and the things you, as professionals, need to know about this medication.   Here's what you'll learn: ·         Indications for and uses of sertraline in Veterinary Medicine (and some super easy ways to remember them). ·         Why sertraline might be a good choice for Canine or Feline Cognitive Dysfunction Syndrome. ·         When sertraline might be a better choice than fluoxetine (if legally possible – the dreaded cascade !!). ·         Potential drug interactions and contraindications.   This is a bit of a whistlestop tour into sertraline but if you'd like to dive even deeper, I've got you covered – My PSYCHOACTIVE course contains everything you need to know: https://katrin-jahn.mykajabi.com/psychoactive   And, if you'd like to learn how sertraline and other Veterinary Psychopharmaceuticals can be applied practically, then The Behaviour Case Collective, where we take a deep-dive into one real-life Behaviour Case every month, might be just the thing for you! https://katrin-jahn.mykajabi.com/behaviour-case-collective   If you'd like to book a 30-minute Vet-Vet or Vet-Pet Care Professional Consultation with me, you can do that right here: https://calendly.com/trinityvet/teams-and-professionals If you can't find an appointment time to suit you, please email us at info@trinityvetbehaviour.com to find a time that suits us both!   And if you'd like some amazing E-Books including Client Handouts and Professional Guides, then have a look here: https://katrin-jahn.mykajabi.com/trinity-ebook     If you liked this episode of the show, Veterinary Behaviour Chat, please LEAVE A 5-STAR REVIEW, like, share, and subscribe!   Facebook Group: Join The Veterinary Behaviour Community on Facebook   You can CONNECT with me: Website: Visit my website Trinity Veterinary Behaviour Instagram: Follow Trinity Veterinary Behaviour on Instagram Trinity Veterinary Behaviour Facebook: Join us on Trinity Veterinary Behaviour's Facebook page Trinity Veterinary Behaviour YouTube: Subscribe to Trinity Veterinary Behaviour on YouTube LinkedIn Profile: Connect with me on LinkedIn   Thank you for tuning in!

THREE Indications there's problems with Digestion by Melina Roberts

When is good enough actually good enough? AI is reshaping how I work and live. And a member with a portfolio that's beaten an all-in-one Vanguard LifeStrategy fund for ten years asks whether the complexity is worth it — or whether it's time to simplify.SponsorsMasterworks - Invest in multimillion-dollar artwork offeringsDelete Me – Use code David20 to get 20% offInsiders Guide Email NewsletterGet our free Investors' Checklist when you sign up for the free Money for the Rest of Us email newsletterOur Premium ProductsAsset CampMoney for the Rest of Us PlusShow NotesThe Upswing: How We Came Together a Century Ago and How We Can Do It Again by Robert Putnam—Simon &SchusterAn update on our model deprecation commitments for Claude Opus 3—AnthropicClaude's Corner—SubstackInvestments MentionedVanguard LifeStrategy Growth Fund Investor (VASGX)Masterworks DisclosuresListeners get priority access to Masterworks at https://www.Masterworks.com/davidArt correlation and appreciation data based on repeat-sales index of historical Post-War & Contemporary Art market prices and S&P 500 annualized return (includes dividends reinvested) from 1995 to 2025, developed by Masterworks. There are significant limitations to comparative asset class data. Indices are unmanaged and a Masterworks investor cannot invest directly in an index. Content creator (the “Endorser”) receives cash compensation from Masterworks, LLC (“Masterworks”). Endorser is a client of Masterworks. Masterworks can only make and accept sales after an offering statement has been filed, and “qualified”, by the SEC. Any offers may be revoked before notice of qualification. Indications of interest involve no obligation. Investing involves risk. Past performance not indicative of future returns. For further disclosure on Regulation A Offerings, Risks of Investing, Performance Metrics, Art Market Data, and more visit the offering documents filed with the SEC and Important Disclosures at masterworks.com/cd.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

93.7 The Fan's Jeff Hathhorn comes on The Fan Hotline to address the latest in Pittsburgh sports with Adam Crowley, Dorin Dickerson and Pat Bostick.

"We print education sheets that we have, and we say, 'Just ignore this part that says cancer. You're getting this med but for a different indication.' And then you have to really point out what our goals of care are. You're using the information that, as oncology nurses, we like and love, but we're having to cross it out and say, 'Just read this portion and just do this here.' And that can be challenging for the nurse and probably confusing for the patient," ONS member Brandy Thornberry, RN, OCN®, outpatient infusion and VAD supervisor at Logan Health in Kalispell, MT, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about education for patients receiving antineoplastic drugs for non-oncology indications. Taylor also spoke with ONS members Lizzy McMahon, BSN, RN, OCN®, and Jennifer Lynch, BSN, RN, TCTCN™, about general antineoplastic treatment education and tailoring education in the stem cell transplantation setting. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 27, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge of best practices for educating patients receiving antineoplastic therapies across oncology, non‑oncology, and stem cell transplant settings. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 259: Patient Education for Health Literacy and Limited English Proficiency Episode 197: Patient Learning Needs and Educational Assessments Episode 183: How Oncology Nurses Find and Use Credible Patient Education Resources Episode 179: Learn How to Educate Patients During Immunotherapy Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease ONS Voice articles: Online Tool Helps You Apply Health Literacy Principles to Written Patient Education Personalized Patient Education: Ensure Effective, Inclusive, and Equitable Patient Education With These Five Strategies Policies and Procedures for Written Patient-Facing Cancer Education Materials Oncology Nursing Forum article: An Integrative Review of Patient Education During Inpatient Hematopoietic Stem Cell Transplantation ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library Patient Education Sheets: Cancer Care, Explained To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode McMahon: "A great question would be to ask the patient what they already know and what they're most concerned about or what their biggest questions are. This way, the nurse can tailor their education to make sure to focus on what the patient doesn't know yet and what they're most concerned about, while still touching on all the required education topics. … It's also important for nurses to continually be assessing the patient's readiness to learn throughout the education session, looking for nonverbal cues or verbal signs that the patient is overwhelmed or anxious because this is going to interfere with their ability to take in new information." TS 3:49 Thornberry: "A lot of the education sheets and the products for them explain it like, 'This is cancer,' and more of an oncology perspective, so occasionally [non-oncology patients] can show up and be confused by it. I do feel like they come a little bit less prepared than our oncology patients. Our rheumatologists and neurologists, they sure try, but they just don't have the support in that realm either. They're full of every question you can imagine. They've never been to an infusion room. They don't know what to bring. Can they drink water and have their meds beforehand? It's a full gamut of really preparing them to get these for autoimmune or rheumatology-type issues." TS 14:12 Lynch: "I really want to spend time with those patients to make sure that we are not assuming that they are coming to us with any knowledge or experience. I want them to be able to come to us with questions and trust their healthcare team and really sit down with them and say, 'Okay, you don't have cancer, but we're using the word chemotherapy where we're talking about cancer drugs.'… And we're going to probably spend more time going over some of the basics about blood stem cells, types of cells that they grow into, how your body fights infection, what they're going to be at risk for. The side effects can be pretty scary when you're talking about them, especially back to back. So making sure that we are delivering the information that doesn't put them in a panic mode… A lot of reassurance, as well, and just taking into consideration that, yes, this might have this whole other layer of anxiety to it because of the unknown." TS 32:22

Welcome to Season 2 of the Orthobullets Podcast. Today's show is Podiums, where we feature expert speakers from live medical events. Today's episode will feature ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. Michael Willey is titled⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ "Acetabular Retroversion and Anteversion: Indications and Outcomes."Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Orthobullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Social Media:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube

In this episode, we look at asset location, how to decide which investments belong in taxable, tax-deferred, and tax-free accounts, how where we live shapes the opportunities available to us, and how capital ultimately expands our choices.SponsorsGelt - Taxes Done RightMasterworks - Invest in multimillion-dollar artwork offeringsDelete Me – Use code David20 to get 20% offInsiders Guide Email NewsletterGet our free Investors' Checklist when you sign up for the free Money for the Rest of Us email newsletterOur Premium ProductsAsset CampMoney for the Rest of Us PlusShow NotesThe Hidden Healthcare Infrastructure Americans Cross the Border to Find—Kogod School of BusinessFARMWORKER SERVICE CENTER PROPOSAL AND ACTION PLAN FOR THE CITY OF CALEXICO AND IMPERIAL VALLEY by JAVIER MORENO—CalexicoLocation as an Asset by Adrien Bilal and Esteban Rossi-Hansberg—PrincetonIt Is Not Climate Denial But Adaptation Denial That Holds Us Back by Mathis Wackernagel and Peter Raven—SSRNThe Overlooked Edge: The Case for Asset Location in Managed Portfolios—MorningstarRevisiting the conventional wisdom regarding asset location by Sachin Padmawar and Daniel Jacobs—VanguardAsset location for equity by Sachin Padmawar and Daniel Jacobs—VanguardThis powerful strategy can create more spendable wealth by Tom Lenkiewicz—J.P. MorganAsset location strategies for tax efficient investing—BlackRockWhat would Yale do? Implementing after-tax asset allocation by Frances Walsh and Patrick Geddes—BlackRockRelated Episodes540: Beyond Munis — New ETFs for Tax-Efficient Bond Investing506: Should You Retire Early and Live Outside Your Home Country? With Joshua Sheats425: How Profits Motivate ChangeMasterworks DisclosuresListeners get priority access to Masterworks at https://www.Masterworks.com/davidArt correlation and appreciation data based on repeat-sales index of historical Post-War & Contemporary Art market prices and S&P 500 annualized return (includes dividends reinvested) from 1995 to 2025, developed by Masterworks. There are significant limitations to comparative asset class data. Indices are unmanaged and a Masterworks investor cannot invest directly in an index. Content creator (the “Endorser”) receives cash compensation from Masterworks, LLC (“Masterworks”). Endorser is a client of Masterworks. Masterworks can only make and accept sales after an offering statement has been filed, and “qualified”, by the SEC. Any offers may be revoked before notice of qualification. Indications of interest involve no obligation. Investing involves risk. Past performance not indicative of future returns. For further disclosure on Regulation A Offerings, Risks of Investing, Performance Metrics, Art Market Data, and more visit the offering documents filed with the SEC and Important Disclosures at masterworks.com/cd.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to Season 2 of the Orthobullets Podcast. Today's show is Podiums, where we feature expert speakers from live medical events. Today's episode will feature ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dr. George Paletta is titled⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ "Management of the Failed SLAP Repair and Biceps Tenodesis Indications.⁠⁠"⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Orthobullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Social Media:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube

Hemorrhoids are far more common than most people realize — affecting more than half of adults at some point in their lives — yet many suffer in silence or believe surgery is their only option.  In today's LIVE episode, we bring together gastroenterology and interventional radiology to discuss the newest minimally invasive treatment: hemorrhoidal artery embolization. Today's Experts • Misha Ginsburg — Interventional Radiologist • Zuhair Yaseen

How can a pastor discern whether it's time to step aside for the health of a declining church? In this episode of the Revitalize & Replant podcast, Mark Clifton and Mark Hallock continue their discussion of an article by Chuck Lawless, focusing on deeper, more sobering indicators that a pastor may have stayed too long in one place. This conversation offers honest reflection for pastors, church leaders, and revitalization teams navigating leadership fatigue, declining momentum, and difficult transition decisions. In this episode, you'll learn additional signs that a pastor may have stayed too long: The church has lost passion and excitement for its mission and ministry. The remaining congregation consists primarily of long-term members with no new growth or generational reach. Financial survival—paying the bills—has overshadowed ministry and mission. The pastor increasingly isolates himself from the church family. The pastor becomes resigned to allowing the church to die on his watch. This episode is especially relevant for pastors serving in declining churches, those considering church revitalization or replanting, and leadership teams seeking wisdom about healthy pastoral transitions. Resources Related to This Episode: “8 Indications that a Pastor of a Declining Church May Have Stayed Too Long” by Chuck Lawless

How can a pastor discern whether it's time to step aside for the health of a declining church? In this episode of the Revitalize & Replant podcast, Mark Clifton and Mark Hallock continue their discussion of an article by Chuck Lawless, focusing on deeper, more sobering indicators that a pastor may have stayed too long in one place.This conversation offers honest reflection for pastors, church leaders, and revitalization teams navigating leadership fatigue, declining momentum, and difficult transition decisions.In this episode, you'll learn additional signs that a pastor may have stayed too long:The church has lost passion and excitement for its mission and ministry.The remaining congregation consists primarily of long-term members with no new growth or generational reach.Financial survival—paying the bills—has overshadowed ministry and mission.The pastor increasingly isolates himself from the church family.The pastor becomes resigned to allowing the church to die on his watch.This episode is especially relevant for pastors serving in declining churches, those considering church revitalization or replanting, and leadership teams seeking wisdom about healthy pastoral transitions.Resources Related to This Episode:“8 Indications that a Pastor of a Declining Church May Have Stayed Too Long” by Chuck Lawless Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease. WHO recently published a guideline in JAMA on the use and indications of GLP-1 therapies for the treatment of #obesity in adults. Francesca Celletti, MD, PhD, and Ezekiel Emanuel, MD, PhD, join JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss. Related Content: World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults